Clinical outcome of a patient cohort with acute hepatitis B

Clinics

Volumn 68, Issue 5, 2013, Pages 718-720

  de Souza, Laura Alves ^a   de Mattos, Angelo Alves ^a   Fiorini, Maristela ^a   Ribeiro, Polyanna ^a   Tovo, Cristiane Valle ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ADULT; ARTICLE; BRAZIL; COHORT ANALYSIS; FEMALE; HEPATITIS B; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; YOUNG ADULT;

ACUTE DISEASE; ADULT; BRAZIL; COHORT STUDIES; FEMALE; HEPATITIS B; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84878443235     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(05)21     Document Type: Article

References (33)

1. European Association for the Study of Liver. EASL Clinical practice guidelines: management of chronic hepatitis J Hepatol. 2009;50(2):227-42.
2. Daruich J, Gadano A, Fainboim H, Pessoa M, Cheinquer H. Guía Latinoamericana de tratamiento de la hepatitis crónica B. Acta Gastroenterol Latinoam. 2007;37(3):168-77.
3. McMahon BJ. Natural history of chronic hepatitis B-clinical implications. Medscape J Med. 2008;10(4):91.
4. Ministério da Saúde (Brasil). Programa Nacional de Imunizações: 30 anos. Brasília: Ministério da Saúde. 2003. [acesso em 2010 Fev.] Disponível em: http://www.scribd.com/doc/27663002/Ministerio-Da-Saude.
5. Ministério da Saúde (Brasil). Nota Técnica 89/2010 CGPNI/DEVEP/ SVS/MS. Ministério da Saúde em 05/08/2010.
6. Ministério da Saúde (Brasil). Portal Brasil. Disponível em: http://www. brasil.gov.br/noticias/arquivos/2012/07/24.
7. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20(4):992-1000, http://dx.doi. org/10.1093/clinids/20.4.992.
8. Lok AS, Mcmahon BJ. AASLD Practice guideline update. Chronic Hepatitis B: Update 2009. Hepatology. 2009;50:1-36.
9. Barker LF, Murray R. Acquisition of hepatitis-associated antigen. Clinical features in young adults. JAMA. 1971;216(12):1970-6, http://dx.doi.org/ 10.1001/jama.1971.03180380028006.
10. Beasley RP, Hwang LY, Lin CC, Ko YC, Twu SJ. Incidence of hepatitis among students at a university in Taiwan. Am J Epidemiol. 1983;117(2):213-22.
11. Ferraz MLG, Yoradjian A, Barbieri A, Figueiredo V, Lopes Neto E, Cruz CN, et al. Epidemiology of acute hepatitis B in a university hospital in São Paulo. Brazil: retrospective study of two five-year periods. Sao Paulo Med J. 1998;116(3):1695-9.
12. Gimeno V, Escudero A, Gonzalez R, Serra MA, Del Olmo JA, Wassel A, et al. Acute hepatitis in heroin addicts: etiologic and follow-up study of 110 cases. Rev Clin Esp. 1989;184(7):360-3.
13. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med. 1978;298(25):1379-83.
14. Kent GP, Brondum J, Keenlyside RA, LaFazia LM, Scott HD. A large outbreak of acupuncture-associated hepatitis B. Am J Epidemiol. 1988;127(3):591-8.
15. Kuruüzüm Z, Ozgenç O, Havuk A, Coşkuner A, Ari A, Celenkoǧlu N. Rate of chronicity and time of disappearance of HBsAg following acute hepatitis B. Hepatogastroenterol. 2009;56(90):466-9.
16. Lavarini C, Farci P, Chiaberge E, Veglio V, Giacobbi D, Bedarida G, et al. IgM antibody against hepatitis B core antigen (IgM anti-HBc): diagnostic and prognostic significance in acute HBsAg positive hepatitis. Br Med J (Clin Res Ed). 1983;287(6401):1254-6, http://dx.doi.org/10.1136/ bmj.287.6401.1254.
17. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151(4):599-603, http://dx.doi.org/10.1093/infdis/151.4. 599.
18. Rinker J, Galambos JT. Prospective study of hepatitis B in thirty-two inadvertently infected people. Gastroenterology. 1981;81(4):686-91.
19. Roumeliotou A, Tassopoulos N, Richardson SC, Kalafatas P, Papaevangelou G. How often does chronic liver disease follow acute hepatitis B in adults? Infection. 1985;13(4):174-6, http://dx.doi.org/10. 1007/BF01642806.
20. Roumeliotou A, Papaevangelou G. Chronic liver disease rarely follows acute hepatitis B in non-immunocompromised adults. Infection. 1992;20(4):221-3, http://dx.doi.org/10.1007/BF02033063.
21. Schomerus H, Wiedmann KH, Dölle W, Peerenboom H, Strohmeyer G, Balzer K, et al. (+), Cyanidanol-3 in the treatment of acute viral hepatitis: a randomized controlled trial. Hepatology. 1984;4(2):331-5, http://dx. doi.org/10.1002/hep.1840040226.
22. Wiedmann KH, Brating NW, Diao GD, Schomerus H, Dolle W, Berg PA. Serum inhibitory factors (SIF) are of prognostic value in acute viral hepatitis. Lancet. 1985;1(8424):309-12, http://dx.doi.org/10.1016/S0140-6736(85)91083-9.
23. Tassopoulos NC, Papaevangelou GJ, Roumeliotou-Karayannis A, Ticehurst JR, Feinstone SM, Purcell RH. Search for hepatitis B virus DNA in sera from patients with acute type B or non-A. non-B hepatitis. J Hepatol. 1986;2(3):410-8, http://dx.doi.org/10.1016/S0168-8278(86) 80052-6.
24. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987;92(6):1844-50.
25. Wands JR, Walker JA, Davis TT, Waterbury LA, Owens AH, Carpenter CC. Hepatitis B in an oncology unit. N Engl J Med. 1974;291(26):1371-5.
26. Kao JH, Chen DS. Global control hepatitis B virus infection. Lancet Infect Dis. 2002;2(7):395-403, http://dx.doi.org/10.1016/S1473-3099(02)00315-8.
27. Daniels D, Grytdal S, Wasley A. Centers for Disease Control and Prevention CDC. Surveillance for acute viral hepatitis-United States. 2007. MMWR Surveill Summ. 2009;58(3):1-27.
28. Kim WR, Benson JT, Therneau TM. Torgerson HA, Yawn BP, Melton LJ. Changing epidemiology of hepatitis B in a U.S. community. Hepatology. 2004;39(3):811-6, http://dx.doi.org/10.1002/hep.20098.
29. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010;82(4):546-55, http:// dx.doi.org/10.1002/jmv.21734.
30. Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology. 2009;49(5 Suppl):S85-95, http://dx.doi.org/10.1002/hep. 22929.
31. Souza MG, Passos ADC, Machado AA, Figueiredo JFC, Esmeraldino LE. Co-infecção HIV e vírus da hepatite B: prevalência e fatores de risco. Rev Soc Bras Med Trop. 2004;37(5):391-5.
32. Tovo CV, Santos DE, Mattos AZ, Almeida PRL, Mattos AA, Santos BR. Prevalência ambulatorial em um hospital geral de marcadores para hepatites B e C em pacientes com infecção pelo vírus da imunodeficiência humana. Arq Gastroenterol. 2006;43(2):73-6, http://dx.doi.org/ 10.1590/S0004-28032006000200002.
33. Sherman M. Strategies for managing coinfection with hepatitis B virus and HIV. Cleve Clin J Med. 2009;76 Suppl 3:S30-3, http://dx.doi.org/10. 3949/ccjm.76.s3.07.